|Action Hero Ventures||South Africa, Stellenbosch, Western Cape|
|Affirma Capital||England, London, United Kingdom|
|Changrun Jinkong||China, Guangdong, Shenzhen|
|Commonwealth's Opportunity Fund||-|
|Crescat Capital||Colorado, Denver, United States|
|Haitong Securities||China, Shanghai|
|HuaJin Securities||China, Shanghai|
|Koerner Capital||Louisiana, New Orleans, United States|
|leAD Sports & Health Tech Partners||Berlin, Berlin, Germany|
|Moonstone Capital||England, London, United Kingdom|
|Omega Pharmaceuticals||England, London, United Kingdom|
|Rumford||Bavaria, Germany, Munich|
|Seazen||China, Guangxi, Zhongjiang|
|The Judd Leighton Foundation||-|
|Yixin Touzi||Beijing, Beijing, China|
|Zhangsheng Guquan||China, Shanxi, Xinjiang|
|$20M||21 Dec 2022||Rehovot, HaMerkaz, Israel|
|$40M||19 Aug 2021||Hangzhou, Zhejiang, China|
|$123M||07 Jan 2021||China, Shanghai|
|$10M||24 Sep 2020||Futian District, Guangdong Province|
|03 Sep 2018||Shanghai, China|
– Ranok Therapeutics (Hangzhou) Co. Ltd. secured a $40m Series B funding round denominated in both U.S. dollars and Chinese yuan.
– The financing was led by Lapam Capital and Shanghai Healthcare Capital, with additional participation from Wu Capital, Zhongguancun Kaiyuan Capital and existing investors, and representatives of the new investors will join Ranok’s expanded board of directors.
– To date, Ranok has raised the equivalent of over $50m in funding.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.